Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
CPRX's Cash to Debt is ranked higher than
90% of the 773 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.62 vs. CPRX: No Debt )
CPRX' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt

Interest Coverage No Debt
CPRX's Interest Coverage is ranked higher than
74% of the 433 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 124.75 vs. CPRX: No Debt )
CPRX' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 19.81
M-Score: -3.97
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -56.82
CPRX's ROE (%) is ranked lower than
53% of the 727 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. CPRX: -56.82 )
CPRX' s 10-Year ROE (%) Range
Min: -568.89   Max: -13.75
Current: -56.82

-568.89
-13.75
ROA (%) -47.91
CPRX's ROA (%) is ranked lower than
54% of the 748 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.87 vs. CPRX: -47.91 )
CPRX' s 10-Year ROA (%) Range
Min: -291.89   Max: -13.24
Current: -47.91

-291.89
-13.24
ROC (Joel Greenblatt) (%) -25151.22
CPRX's ROC (Joel Greenblatt) (%) is ranked lower than
57% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.91 vs. CPRX: -25151.22 )
CPRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -54300   Max: -1217.19
Current: -25151.22

-54300
-1217.19
Revenue Growth (%) -100.00
CPRX's Revenue Growth (%) is ranked lower than
59% of the 629 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. CPRX: -100.00 )
CPRX' s 10-Year Revenue Growth (%) Range
Min: 0   Max: -100
Current: -100

EBITDA Growth (%) 1.50
CPRX's EBITDA Growth (%) is ranked higher than
66% of the 594 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.60 vs. CPRX: 1.50 )
CPRX' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 42
Current: 1.5

0
42
EPS Growth (%) 7.10
CPRX's EPS Growth (%) is ranked higher than
73% of the 595 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.00 vs. CPRX: 7.10 )
CPRX' s 10-Year EPS Growth (%) Range
Min: -33.7   Max: 40.8
Current: 7.1

-33.7
40.8
» CPRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

CPRX Guru Trades in

CPRX Guru Trades in

Q3 2013

CPRX Guru Trades in Q3 2013

Jim Simons 138,500 sh (New)
» More
Q4 2013

CPRX Guru Trades in Q4 2013

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CPRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 6.80
CPRX's P/B is ranked higher than
52% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.22 vs. CPRX: 6.80 )
CPRX' s 10-Year P/B Range
Min: 1.5   Max: 11.71
Current: 6.8

1.5
11.71
EV-to-EBIT -12.91
CPRX's EV-to-EBIT is ranked lower than
51% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.81 vs. CPRX: -12.91 )
CPRX' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -12.91

Current Ratio 9.10
CPRX's Current Ratio is ranked higher than
94% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. CPRX: 9.10 )
CPRX' s 10-Year Current Ratio Range
Min: 0.75   Max: 54.56
Current: 9.1

0.75
54.56
Quick Ratio 9.10
CPRX's Quick Ratio is ranked higher than
94% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. CPRX: 9.10 )
CPRX' s 10-Year Quick Ratio Range
Min: 0.75   Max: 54.56
Current: 9.1

0.75
54.56

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.30
CPRX's Price/Net Cash is ranked higher than
93% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. CPRX: 7.30 )
CPRX' s 10-Year Price/Net Cash Range
Min: 1.36   Max: 18.63
Current: 7.3

1.36
18.63
Price/Net Current Asset Value 7.30
CPRX's Price/Net Current Asset Value is ranked higher than
90% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. CPRX: 7.30 )
CPRX' s 10-Year Price/Net Current Asset Value Range
Min: 1.36   Max: 18.63
Current: 7.3

1.36
18.63
Price/Tangible Book 6.90
CPRX's Price/Tangible Book is ranked higher than
59% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. CPRX: 6.90 )
CPRX' s 10-Year Price/Tangible Book Range
Min: 1.24   Max: 10.09
Current: 6.9

1.24
10.09
Forward Rate of Return (Yacktman) -25.52
CPRX's Forward Rate of Return (Yacktman) is ranked higher than
50% of the 622 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.97 vs. CPRX: -25.52 )
CPRX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -25.52

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:CN2.Germany
Catalyst Pharmaceutical Partners, Inc. was incorporated in Delaware in July 2006. The Company is a development-stage specialty pharmaceutical Company focused on the development and commercialization of prescription drugs targeting diseases and disorders of the central nervous system with a focus on the treatment of addiction and epilepsy. It has two products in development. It is currently evaluating its drug candidate, CPP-109 (its formulation of vigabatrin, a GABA aminotransferase inhibitor) for the treatment of cocaine addiction. CPP-109 and CPP-115 have both been granted 'Fast Track' status by the FDA for the treatment of cocaine addiction, which indicates that the FDA has recognized that CPP-109 and CPP-115 are intended for the treatment of a serious or life-threatening condition for which there is no effective treatment and which demonstrates the potential to address unmet medical needs. The Company is in the early stages of developing CPP-115, another GABA aminotransferase inhibitor. It is planning to develop CPP-115 for several indications, including drug addiction, epilepsy (initially infantile spasms) and other selected central nervous disease indications. The Company competes against pharmaceutical companies that are developing or currently marketing therapies for addictive substances. The Company also competes against biotechnology companies, universities, government agencies, and other research institutions in the development of substance abuse treatments, technologies and processes.
» More Articles for CPRX

Headlines

Articles On GuruFocus.com
Largest Insider Buys of the Week Oct 25 2013 
Weekly CFO Buys Highlight: CPRX, APPY, MEI, MNKD Jul 09 2012 
Weekly CFO Buys Highlight: EMC, DVOX, NANX, CPRX, CCRN Jun 04 2012 
Catalyst Pharmaceutical Partners Inc. Reports Operating Results (10-Q) Nov 15 2010 
Catalyst Pharmaceutical Partners Inc. Reports Operating Results (10-Q) Aug 12 2010 
Catalyst Pharmaceutical Partners Inc. (CPRX) CEO Patrick J Mcenany buys 9,359 Shares Jun 16 2010 
Catalyst Pharmaceutical Partners Inc. Reports Operating Results (10-Q) May 17 2010 
Catalyst Pharmaceutical Partners Inc. (CPRX) CEO Patrick J Mcenany buys 25,000 Shares Nov 16 2009 
Catalyst Pharmaceutical Partners Inc. Reports Operating Results (10-Q) Nov 12 2009 
Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results Aug 07 2009 

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide